poisar

Stock

Rocket Pharmaceuticals, Inc. RCKT

$3.67-2.78%

Overview

RCKT market data

Price History

RCKT price chart · 1M
O
3.70
H
3.70
L
3.58
C
3.67
Vol
54,616.00
Source
US equities market feed
Observed
Aug 26, 2026, 12:00 AM
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & Performance

Open
$3.70
Previous Close
$3.78
Day High
$3.70
Day Low
$3.58
52 Week High
$5.45
52 Week Low
$2.53
7 Day Return
+0.41%
30 Day Return
+13.27%
90 Day Return
+21.93%
1 Year Return
-16.78%
Daily Notional Volume
$200.4K
Latest daily bar volume multiplied by its closing price.

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$2.01
Diluted earnings per share over the trailing twelve months.
Beta
0.46
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$2.53 – $5.45
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $368.3M · P/B 1.37.

Company News

5 captured
Wedbush Maintains Outperform on Rocket Pharmaceuticals, Lowers Price Target to $15Benzinga · Aug 11, 2026, 1:52 PM
Rocket Pharmaceuticals Q2 Adj. EPS $(0.37) Misses $0.24 EstimateBenzinga · Aug 10, 2026, 8:21 PM
Rocket Pharmaceuticals Touts Positive Early Safety Data from Revised Genetic Therapy TrialBenzinga · Aug 3, 2026, 4:03 PM
Rocket Pharma Announces Clinical Safety Update Regarding Initial Three Patients Treated Under Modified Protocol For Global, Pivotal Phase 2 Trial Of RP-A501 In Danon DiseaseBenzinga · Aug 3, 2026, 11:14 AM
Rocket Pharmaceuticals Closes Sale Of Its Rare Pediatric Disease Priority Review Voucher For Gross Proceeds Of $180MBenzinga · Jun 12, 2026, 11:05 AM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock